


CLAIMS

What is claimed is:

1. A compound of Formula 1



1

or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein:

R₁ is H or methyl;

each of R₂ and R₃ is independently H, halogen, (C₁-C₃)alkyl, or (C₁-C₃)alkoxy; or R₂ and R₃ taken together form an optionally substituted methyldene or a 3- to 7-membered ring optionally comprising 0-3 heteroatoms;

R₄ is H, methyl, trifluoromethyl, (C₁-C₄)alkyl, alkoxy, amido, amino, or optionally substituted aryl;

X is a chemical bond, ethynyl, -O-, -S-, -S(O)-, -S(O₂)-, -NR₅C(O)-, or -NR₅-,
wherein R₅ is H, methyl, or substituted methylene;

Y is a 5- to 10-membered mono or bicyclic, saturated, unsaturated, or aromatic ring comprising 0-3 heteroatoms and optionally substituted; and

Z is N or CR₆, wherein R₆ is H, halogen, nitro, cyano, alkoxy, sulfonamide, amino, or amide.

2. The compound of claim 1 wherein X is a chemical bond, -O-, -S-, or -NR₅-.


3. The compound of claim 1 wherein Y is selected from the group consisting of phenyl, indolyl, indolinyl, 1H-indazolyl, 2,3-dihydro-1H-indazolyl, 1H-benzimidazolyl, 2,3-dihydro-1H-benzimidazolyl, benzotriazolyl, pyridyl, pyrimidyl, 4-substituted piperazin-1-yl, morpholino, piperidinyl, pyrrolidin-1-yl, furanyl, thiophenyl, pyrrolyl, pyrazolyl, imidazolyl, pyridopyrrolyl, pyridazopyrrolyl, pyrimidopyrrolyl, pyrazopyrrolyl, pyridofuranyl, and derivatives thereof.

4. The compound of claim 1 wherein Z is N or CH.

5. The compound of claim 1 wherein R₂ and R₃ are both H, halogen, or methyl.

6. The compound of claim 1 wherein R₂ and R₃ are taken together to form a ring selected from the group consisting of 1,3-dioxolane, 1,3-dioxane, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

7. The compound of claim 1 wherein R₂ and R₃ are taken together to form an optionally substituted methyldiene selected from those of Formulas 1a-1n:



wherein:

n is an integer of 0-3;

each R₇ is independently H, alkyl, carboxylic acid, amine, halogen, nitro, cyano, X₁, X₂-(C-C₄)alkyl-R₈, X₂-(C₁-C₄)alkenyl-R₈, or X₂-(C₁-C₄)alkynyl-R₈;

X₁ is -C(O)NR₉-, -NR₉C(O)-, -C(O)O-, C(O)R₁₁, -OC(O)-, -O-, -NR₉-, -S-, -S(O₂), or -S(O₂)NR₉-;

X_2 is a chemical bond, $-C(O)NR_9-$, $-NR_9C(O)-$, $-C(O)O-$, $C(O)R_{11}$, $-OC(O)-$, $-O-$, $-NR_9-$, $-S-$, $-S(O_2)$, or $-S(O_2)NR_9$;

R_8 is selected from the group consisting of hydrogen, dialkylamino, carboxyl, hydroxyl, alkoxy, sulfonamide, urea, carbamate, diol, alkylsulphonyl, and R_{10} ;

R_9 is H or $(C_1-C_3)\text{alkyl}$;

R_{10} is an optionally substituted 5- or 6-membered saturated, unsaturated, or aromatic heterocycle comprising from 1 to 4 heteroatoms; and







R_{11} is an optionally substituted 5- to 6-membered saturated heterocyclic ring.











8. The compound of claim 7 wherein R_7 is $X_2-(C_1-C_4)\text{alkyl}-R_8$, $X_2-(C_1-C_4)\text{alkenyl}-R_8$, or $X_2-(C_1-C_4)\text{alkynyl}-R_8$, and R_8 is selected from the group consisting of alkylsulfonyl, alkoxy, carboxyl, morpholino, 1-alkyl-piperazin-4-yl, pyrrolidinyl, piperidinyl, pyridyl, imidazolo, triazolo, tetrazolo, and thiazolo.


9. The compound of claim 1 wherein R_4 is H, methyl, or trifluoromethyl.

10. The compound of claim 1 wherein if Z is CH, R_1 is CH_3 or R_3 and R_2 do not form an optionally substituted methylindene.


11. A compound selected from the group consisting of:









19




20




21




22




23




24




25




26




27




28




29




30




31




32




33




34




35




36




37




38




39




40




41




42




43




44




45




46




47




48




49




50




51




52




53




54




55



56




57



58

and pharmaceutically acceptable salts, solvates, clathrates, and prodrugs thereof.

12. A method of preparing a compound of Formula 2:



or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein:

R₁ is H or methyl;

R₄ is H, methyl, trifluoromethyl, (C₁-C₄)alkyl, alkoxy, amido, amino, or optionally substituted aryl;

X is a chemical bond, ethynyl, -O-, -S-, -S(O)-, -S(O₂)-, -NR₅C(O)-, or -NR₅-, wherein R₅ is H, methyl, or substituted methylene;

Y is a 5- to 10-membered mono or bicyclic, saturated, unsaturated, or aromatic ring comprising 0-3 heteroatoms and optionally substituted; and

Z is N or CR₆, wherein R₆ is H, halogen, nitro, cyano, alkoxy, sulfonamide, amino, or amide;

n is an integer of 0-3;

each R₇ is independently H, alkyl, carboxylic acid, amine, halogen, nitro, cyano, X₁, X₂-(C-C₄)alkyl-R₈, X₂-(C₁-C₄)alkenyl-R₈, or X₂-(C₁-C₄)alkynyl-R₈;

X₁ is -C(O)NR₉-, -NR₉C(O)-, -C(O)O-, C(O)R₁₁, -OC(O)-, -O-, -NR₉-, -S-, -S(O₂), or -S(O₂)NR₉-;


X₂ is a chemical bond, -C(O)NR₉-, -NR₉C(O)-, -C(O)O-, C(O)R₁₁, -OC(O)-, -O-, -NR₉-, -S-, -S(O₂), or -S(O₂)NR₉-;

R₈ is selected from the group consisting of hydrogen, dialkylamino, carboxyl, hydroxyl, alkoxy, sulfonamide, urea, carbamate, diol, alkylsulphonyl, and R₁₀;

R₉ is H or (C₁-C₃)alkyl;

R₁₀ is an optionally substituted 5- or 6-membered saturated, unsaturated, or aromatic heterocycle comprising from 1 to 4 heteroatoms; and

R₁₁ is an optionally substituted 5- or 6-membered saturated heterocyclic ring; which comprises reacting a compound of the formula:



wherein L is a leaving group with a compound of formula YXH under conditions sufficient to form a compound of Formula 2.


13. The method of claim 12 wherein L is selected from the group consisting of Br, Cl, SCH₃, and S(O)CH₃.

14. The method of claim 12 wherein the reaction is performed in a polar solvent.


15. The method of claim 14 wherein the polar solvent is selected from the group consisting of alcohols, DMF, and DMSO.

16. The method of claim 12 wherein the reaction is catalyzed by a catalyst selected from the group consisting of AgOTf, Pd(Ph₃)₄, and *p*-TsOH.

17. A method of preparing a compound of Formula 2 which comprises reacting a compound of the formula:



with a compound of the formula:



under conditions sufficient to form a compound of Formula 2.

18. The method of claim 17 wherein the reaction is performed in a polar solvent.

19. The method of claim 18 wherein the polar solvent is selected from the group consisting of alcohols, DMF, and DMSO.

20. The method of claim 17 which is catalyzed by a base.
21. The method of claim 20 wherein the base is selected from the group consisting of pyridine and piperidine.
22. A pharmaceutical composition comprising a compound of Formula 1, or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, and a pharmaceutically acceptable carrier.
23. The pharmaceutical composition comprising a compound of claim 11 and a pharmaceutical acceptable carrier or excipient.
24. The pharmaceutical composition of claim 22 which is suitable for oral, transdermal, topical, parenteral, or mucosal administration.
25. A method of regulating, modulating, or inhibiting protein kinase activity which comprises contacting a compound of Formula 1, or a pharmaceutically acceptable salt or solvate thereof, with a protein kinase.
26. The method of claim 25 wherein the protein kinase is a protein tyrosine kinase.
27. The method of claim 25 wherein the protein kinase is selected from the group consisting of abl, ATK, bcr-abl, Blk, Brk, Btk, c-fms, c-kit, c-met, c-src, CDK1, CDK2, CDK4, CDK6, cRaf1, CSF1R, CSK, EGFR, ErbB2, ErbB3, ErbB4, ERK, Fak, fes, FGFR1, FGFR2, FGFR3, FGFR4, FGFR5, Fgr, FLK-4, flt-1, Fps, Frk, Fyn, GSK, Gst-Flk1, Hck, Her-2, Her-4, IGF-1R, INS-R, Jak, JNK, KDR, Lck, Lyn, MEK, p38, PANHER, PDGFR, PLK, PKC, PYK2, Raf, Rho, ros, SRC, tie₁, tie₂, TRK, UL97, VEGFR, Yes, and Zap70.
28. The method of claim 27 wherein the protein kinase is selected from the group consisting of PANHER, EGFR, Her-2, Her-4, PDGFR, SRC, Lck, cdk2, p38, Raf, and Rho.
29. The method of claim 28 wherein the protein kinase is selected from the group consisting of PANHER, CDK2, PDGFR, p38, and Raf.
30. The method of claim 25 wherein the protein kinase is in a cell culture.
31. The method of claim 25 wherein the protein kinase is in a mammal.

32. A method of treating or preventing a mammalian disease characterized by unregulated protein kinase activity which comprises administering to a mammal in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of Formula 1, or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof.

33. The method of claim 30 wherein the disease characterized by unregulated protein kinase activity is selected from the group consisting of: blood vessel proliferative disorders; fibrotic disorders; mesangial cell proliferative disorders; metabolic disorders; allergies; asthma; thrombosis; nervous system diseases; and cancer.

34. The method of claim 31 wherein the disease characterized by unregulated protein kinase activity is cancer.

35. The method of claim 32 wherein the cancer is selected from the group consisting of breast, stomach, ovary, colon, lung, brain, larynx, lymphatic system, genitourinary tract (including bladder and prostate), ovarian, gastric, bone, and pancreatic cancer.